Osimertinib combined with chemotherapy as fi rst-line treatment in EGFR-mutant advanced NSCLC patients: The fi rst real-world analysis in China

被引：0
|
作者：
Ji, W. [1 ]
Yu, Y. [1 ]
Ai, X. [1 ]
Chen, Z. [1 ]
Zhou, Z. [1 ]
Li, Z. [1 ]
机构：
[1] Shanghai Liao Tong Univ, Shanghai Chest Hosp, Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy fi cacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after fi rst-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
    Zhou, Yue
    Peng, Lin
    Liang, Fei
    Chu, Li
    Chu, Xiao
    Yang, Xi
    Zhang, Junhua
    Guo, Tiantian
    Jiang, Shanshan
    Pang, Yechun
    Wang, Zezhou
    Zhang, Li
    Ni, Jianjiao
    Zhu, Zhengfei
    ECLINICALMEDICINE, 2024, 76
  • [32] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
  • [33] Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
    Sabari, J.
    Pisano, S.
    Gemmler, K.
    Mueller, J.
    Bernabe Caro, R.
    Girard, N.
    Goto, K.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Lee, S. -H.
    Demirdjian, L.
    Harvey, R.
    Rudolph, S.
    Mahadevia, P.
    Bauml, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S488 - S489
  • [34] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [35] Tislelizumab plus chemotherapy as fi rst-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)
    Lu, S.
    Wang, J.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    He, W.
    Bao, Y.
    Wang, M.
    ESMO OPEN, 2024, 9 (10)
  • [36] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
    Chen, Kuan-Chih
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326
  • [37] Osimertinib versus First-Generation EGFR-TKIs in Untreated EGFR-Mutant NSCLC with Brain Metastasis: 362 Real-World Cases
    Zhao, Y.
    Li, S.
    Zhu, Z.
    Ni, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S624 - S625
  • [38] Capecitabine combined with PD-1 antibody as maintenance therapy after fi rst-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study
    Li, Y.
    Chen, Y.
    Cheng, H.
    Shen, J.
    Shen, B.
    Long, H.
    Sun, X-s.
    Chen, J.
    Peng, J.
    Wang, P.
    Guo, S-s.
    Chen, Q. Y.
    Tang, L. Q.
    Mai, H.
    Liu, L.
    ANNALS OF ONCOLOGY, 2024, 35
  • [39] A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
    Li, Liu
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hou, Ting
    Lizaso, Analyn
    Chen, Zhiqiu
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R. Rasim
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    LUNG CANCER, 2019, 127 : S37 - S37
12345